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Abstract 
BACKGROUND: Venoarterial extracorporeal membranous oxygenation is a form of temporary mechanical 
circulatory support that gets as a salvage technique in patients with cardiogenic shock, we intended to evaluate 
the effect of (VA ECMO) support on hemodynamics and lactate levels in patients with cardiogenic shock. 
AIM: The aim of our study is to detect the ability to introduce veno-arterial extracorporeal membranous 
oxygenation (VA ECMO) as a temporary extracorporeal life support system (ECLS) in our unit, demonstrate the 
role of ECMO in cardiogenic shock patients regarding improving hemodynamics and microcirculation, and 
demonstrate the complications and drawbacks in our first center experience regarding VA ECMO. 
MATERIAL AND METHODS: This was a single-centre observational study that included 10 patients admitted 
with cardiogenic shock for which VA ECMO was used as mechanical circulatory support.  
RESULTS: The MAP increased after initiation of the support. It was 41.8 ± 9.3 mmHg and 59.5 ± 6.8 mmHg (P = 
0.005). The use of VA ECMO support was associated with a statistically significant decrease in the base deficit (-
10.6 ± 4.2 and -6.3 ± 7.4, P = 0.038). The serum lactate declined from 5.9 ± 3.5 mmoL/L to 0.6 ± 4.4 mmoL/L by 
the use of VA ECMO; a statistically significant change (P = 0.005). 
CONCLUSIONS: We concluded that VA ECMO as mechanical support for patients with cardiogenic shock might 
improve mean arterial blood pressure, base deficit and lactate clearance. 
 
 
 
 
 
 
 
 
Introduction 
 
Cardiogenic shock is a physiologic state 
where end-organ tissue hypoperfusion is a result of 
cardiac dysfunction. Despite many advances in the 
management of cardiogenic shock, mortality rates are 
still high [1]. 
Coronary revascularisation is the mainstay of 
therapy for cardiogenic shock caused by myocardial 
infarction. However, after reperfusion, areas of the 
myocardium may have myocardial stunning that 
persists despite the restoration of normal blood flow. 
These areas may improve with revascularisation, 
providing a strong rationale for supporting 
hemodynamics in cardiogenic shock [2]. 
The initial therapy of cardiogenic shock 
involves careful infusion of fluids. If the shock is 
persistent, then pharmacologic therapy with inotropic 
and vasopressor agents is started. The use of 
inotropes and vasopressors in cardiogenic shock 
treatment increases myocardial oxygen demand. 
However, studies have not necessarily demonstrated 
that their use decreases mortality rates [2]. 
Mortality in cardiogenic shock patients occurs 
mainly in the first three days, so mechanical 
circulatory support devices should be considered as 
soon as possible. The results of studies on such 
devices are promising in improving microcirculation 
and microcirculation. Also, these devices are 
recommended for patients in persistent shock after 
inotropic and vasopressor therapy [3]. 
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While the intra-aortic balloon counterpulsation 
(IABP) use is limited in complicated myocardial 
infarction cases, other mechanical circulatory support 
devices such as extracorporeal membrane 
oxygenation (ECMO) can be used in other causes of 
cardiogenic shock such as pulmonary embolism. 
However, there are still no randomised controlled 
studies on the use of VA ECMO in patients with 
cardiogenic shock. 
The aim of our study is to detect the ability to 
introduce veno-arterial extracorporeal membranous 
oxygenation (VA ECMO) as a temporary 
extracorporeal life support system (ECLS) in our unit, 
demonstrate the role of ECMO in cardiogenic shock 
patients regarding improving hemodynamics and 
microcirculation, and demonstrate the complications 
and drawbacks in our first center experience 
regarding VA ECMO. Our centre is the first centre in 
Egypt to be recognised as an ECMO centre by the 
Extracorporeal Life Support Organization.  
 
 
Patients and Methods 
 
This study is a prospective observational 
study on patients admitted to the Critical Care 
Department, Cairo University Hospitals with 
cardiogenic shock from January 2015 to April 2017.  
The present study included patients with 
cardiogenic shock within 6 hours of shock 
development, either upon admission to the intensive 
care unit (ICU) or during ICU stay. The excluded 
patients from the study are those with irreversible 
cause for cardiogenic shock or those with cardiogenic 
shock after 6 hours duration with signs of neurologic 
damage, prolonged multiorgan dysfunction, or futility. 
The patients enrolled in our study were 
subjected to full medical history and thorough clinical 
examination (general and cardiac). Hemodynamics 
and vital signs such as mean arterial pressure (MAP), 
heart rate (HR), respiratory rate (RR), and 
temperature were obtained at the time of support 
initiation (hemodynamics 0) and 24 hours after 
initiation (hemodynamics 1). All patients were 
subjected to routine laboratory investigations including 
complete blood picture, coagulation profile, renal 
functions, liver functions, blood gases, and lactate 
level. Two readings were obtained at the time of 
support initiation (laboratory 0) and 24 hours after 
initiation (laboratory 1). 
Chest X-ray, 12-lead ECG, and transthoracic 
echocardiography (aortic velocity time integral (VTI)) 
was done to all patients before mechanical support 
initiation (echocardiography 0), 24 hours after initiation 
(echocardiography 1), and whenever needed after 
that.  
Acute physiological and chronic health 
evaluation (APACHE II) scoring system, sequential 
organ failure assessment score (SOFA score), and 
vasoactive-inotropic score (VIS) were obtained at the 
time of support initiation (score 0) and 24 hours after 
initiation (score 1). 
Cardiohelp maquet console (HLS ECMO 
circuit) was used in 7 patients, while Rotaflow maquet 
(PLS ECMO circuit) was used in 3 patients. 
The HLS ECMO circuit integrates a gas 
exchanger (equipped with a diffusion membrane), 
highly efficient heat exchanger, and a centrifugal 
pump. Also, the integrated measuring cell is used to 
measure the important blood parameters of venous 
oxygen saturation (SVO2), hematocrit (Hct), 
haemoglobin (Hb), and venous temperature (Tven). 
Unlike the Cardiohelp, the Rotaflow console is 
not portable and only has a sensor to detect the flow. 
The console, oxygenator, and pump are separated. 
The PLS ECMO set is bio line-coated. 
This study was approved by the Ethical 
Committee Review Board of the Faculty of Medicine, 
Cairo University. Informed written consent was 
acquired from patients or relatives before their 
enrollment in the study. 
 
Statistical Methods 
Numerical variables were described as Mean 
± standard deviation (SD). Categorical variables were 
described as proportions. Student ‘t’ test was used for 
comparisons of numerical data, with Levene test for 
equality of variance and paired ‘t’ test for paired 
comparisons. Chi-square test 2*2 was applied with 
Ficher exact test for comparison between categorical 
data. McNemar test was applied for a total less than 
40 or any of observed events less than 5. P value was 
considered significant if ≤ 0.05. Delta change, i.e. the 
per cent of change, was calculated as the difference 
between the second and first reading divided by the 
first reading. Statistics were calculated using SPSS 21 
package. 
 
 
Results 
 
We initially recruited 15 patients who were 
admitted with cardiogenic shock. Five patients were 
excluded because 3 of them had septic shock, and 
the rest (2 patients) were futile without any sign of 
neurological recovery.  
Our study included 10 patients (7 males and 3 
females with an average age of 43.4 ± 17.2 years) 
who were in cardiogenic shock and was supported by 
VA ECMO. 
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Patients enrolled in our study were admitted 
to the Critical Care Medicine Department, Cairo 
University Hospitals during the period from January 
2015 to April 2017. Six patients had a myocardial 
infarction, 1 patient during CPR and another patient 
after CPR, two patients had a pulmonary embolism, 
and two patients had stress-induced cardiomyopathy. 
 
Hemodynamic monitoring 
Paired comparisons were made to show the 
effect of VA ECMO support on hemodynamics. These 
comparisons showed a significant difference between 
MAP (0) and MAP (1) [41.8 ± 9.3 and 59.5 ± 6.8, P 
value = 0.005] and another significant difference 
between RR (0) and RR (1) [38.0 ± 11.8 and 28.0 ± 
12.2, P value = 0.006]. 
Table 1: Comparison between hemodynamics (0) and 
hemodynamics (1)  
 Hemodynamics(0) Hemodynamics(1) P value 
Temperature 37.4 ± 0.8 37.5 ± 0.7 .730 
MAP 41.8 ± 9.3 59.5 ± 6.8 .005 
HR 134.3 ± 15.1 113.4 ± 19.7 .076 
RR 38.0 ± 11.8 28.0 ± 12.2 .006 
MAP: Mean arterial pressure; HR: Heart rate; RR: Respiratory rate. 
 
Blood gases 
The paired comparisons done to show the 
effect of VA ECMO on blood gases showed a 
statistically significant difference between HCO3 (0) 
and HCO3 (1) [14.7 ± 2.3 and 18.3 ± 5.5, P value= 
0.042] and another statistically significant difference 
between base deficit (0) and base deficit (1) [-10.6 ± 
4.2 and -6.3 ± 7.4, P value = 0.038]. 
Table 2: Comparison between blood gases (0) and blood gases 
(1)  
 Blood gases (0) Blood gases (1) P value 
PH 7.2 ± 0.1 7.3 ± 0.2 .155 
HCO3 14.7 ± 2.3 18.3 ± 5.5 .042 
Base deficit -10.6 ± 4.2 -6.3 ± 7.4 .038 
PaO2 52.7 ± 19.7 58.1 ± 18.8 .009 
 
 
Laboratory values 
Paired comparisons were done to show the 
effect of VA ECMO on laboratory values where they 
showed a statistically significant difference between 
platelet (0) and platelet (1) [197.3 ± 81.9 and 146.7 ± 
72.5, P value = 0.005] and another statistically 
significant difference between lactate (0) and lactate 
(1) [5.9 ± 3.5 and 4.6 ± 4.4, P value = 0.005]. 
Table 3: Comparison between Laboratory (0) and Laboratory 
(1)  
 Laboratory (0) Laboratory (1) P value 
Sodium 140.1±4.7 141.4±4.4 .362 
Potassium 4.0±1.1 3.9±0.4 .788 
Creatinine 2.3±1.8 2.5±1.5 .757 
Bilirubin 1.0±0.8 1.8±1.5 .138 
Hematocrit 30.1±9.4 29.2±5.4 .793 
White blood cell 28.6±18.1 25.7±15.0 .304 
Platelets 197.3±81.9 146.7±72.5 .005 
Lactate 5.9±3.5 4.6±4.4 .005 
Clinical severity scores 
Comparison between clinical scores (0) and 
clinical scores (1) in group 2 are shown in Table 4. 
Table 4:  Comparison between clinical scores (0) and clinical 
scores (1) in group 2 
 clinical scores (0) clinical scores (1) P value 
GCS 12.3 ± 3.6 9.9 ± 4.6 .120 
APACHE II 25.3 ± 6.8 20.9 ± 9.8 .092 
SOFA 11.9 ± 2.9 11.1 ± 2.9 .140 
Vasoactive inotropic score 89.3 ± 62.1 36.7 ± 28.6 .073 
GCS: Glasgow coma scale. 
 
Echocardiographic examination 
Echocardiographic examination was done to 
measure LVEF, aortic VTI and PASP. No significant 
differences were demonstrated when comparing the 
values of these parameters pre and post-mechanical 
support. 
Table 5:  Comparison between echocardiography (0) and 
echocardiography (1) in group 2 
 Echocardiography (0) Echocardiography (1) P value 
LVEF 40.3 ± 25.1 39.3 ± 20.9 .806 
Aortic VTI 12.9 ± 8.6 12.9 ± 7.7 1.000 
PASP 44.3 ± 20.6 40.4 ± 16.4 .058 
 
 
The outcome of VA ECMO 
The duration of support was 4.3 ± 3.1 days 
with average ICU stay 12.4 ± 12.7. In our 10 patients 
who received VA ECMO, 5 patients experienced 
complications, 2 patients suffered thrombocytopenia, 
2 patients suffered cerebrovascular accidents, and 1 
patient suffered limb ischemia. 
Four patients were weaned off the mechanical 
support, but only one patient survived to hospital 
discharge. 
 
 
Discussion 
 
Percutaneous hemodynamic support has 
historically been limited to the IABP counterpulsation. 
Although the IABP is widely available, its limitations 
include little hemodynamic support and myocardial 
protection, while VA ECMO can provide full 
hemodynamic support, but it is limited by complexity, 
multiple complications, high cost, and need for 
perfusion expertise [3].  
 The benefits of mechanical circulatory 
support include the ability to maintain organ perfusion 
which, accordingly, prevents systemic shock 
syndrome, reducing the intracardiac filling pressures, 
right and leaves ventricular volumes, wall stress as 
well as myocardial oxygen consumption, augmenting 
coronary perfusion, and supporting the circulation 
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during complex interventional procedures [3].
  
In our centre, the mechanical support with 
VA-ECMO is recently used for cardiogenic shock 
management. We used VA ECMO as mechanical 
circulatory support for a total of 10 cardiogenic shock 
patients with an increase in mean arterial pressure 
after the support initiation. The improvement of 
hemodynamics and oxygenation occurred after VA 
ECMO support initiation led to a significant reduction 
in the base deficit and lactate level.  
There is a contradiction about the benefit of 
combined IABP and VA-ECMO support in patients 
with cardiogenic shock. In our study, we combined the 
use of VA ECMO and IABP in 3 patients to decrease 
the afterload. This combination led to weaning one 
patient from the ECMO support 48 hours after 
implementation of IABP.  
A study was done by Petroni et al., [4]
 
which 
included 12 patients on VA ECMO concluded that in 
cardiogenic shock patients with little or no residual left 
ventricular ejection implanted by peripheral VA 
ECMO, the use of intra-aortic balloon pump was 
associated with smaller left ventricular dimensions 
and lower pulmonary artery pressures due to the 
restoration of pulsatility and decrease of left 
ventricular afterload. A study conducted by Sattler et 
al., [5] on 24 patients with STEMI and NSTEMI, in 
which 12 patients were supported by VA ECMO and 
the other 12 patients were supported by IABP, 
showed that the percentage of 30-day survival was 
67% in VA ECMO-supported patients vs 33% in IABP-
supported patients. 
A retrospective cohort study, including 1,650 
cardiogenic shock adult patients concluded that IABP, 
combined with VA-ECMO support, was associated 
with reduced mortality and successful weaning from 
VA-ECMO [6]. In another study done on 529 patients 
who received peripheral VA ECMO, where a group of 
them received combined ECMO and IABP treatment 
while the other group received ECMO support only, 
the researchers found that the mortality rate at 2 
weeks was not different between the two groups. 
Moreover, more patients in the combined group 
received limb fasciotomy operations due to vascular 
complications [7]. 
ECMO-CPR was instituted in 2 of our study 
patients; however, they were deceased. A study by 
Shin et al., [8] suggested that patients who receive 
extracorporeal cardiopulmonary resuscitation (CPR) 
for longer than 10 minutes following in-hospital arrest 
have a greater chance of survival when compared to 
those who receive conventional CPR. The survival 
discharge rate with minimal neurologic impairment in 
the extracorporeal CPR group was significantly higher 
than that in the conventional CPR group. 
In our study, we used VA ECMO in two 
patients with pulmonary embolism. In a study of 
10years period (2005-2015) that included 17 patients 
with confirmed or suspected pulmonary embolism, 
Fifteen patients (82%) suffered pre-ECMO cardiac 
arrest, with seven (41%) of them cannulated during 
cardiopulmonary resuscitation, 10 (59%) patients 
were weaned off ECMO and 8 patients (47%) were 
discharged. The study concluded that VA ECMO 
could be a lifesaving rescue therapy to rapidly restore 
the hemodynamic status when thrombolytic therapy 
fails or when the patient is deemed too sick to benefit 
from medical or surgical treatments [9].  
In our study, none of the analysed variables 
was of help in predicting successful weaning from 
ECMO or heart function recovery. However, other 
studies have correlated echocardiographic [10] and 
clinical parameters as well as laboratory tests results 
[11] to the prediction of weaning. The lack of results in 
our series may be due to the limited number of 
patients involved in addition to the study design, which 
was not intended to examine this aspect.  
In our study, 40% of patients could be 
weaned from mechanical support. This agrees with 
Muller et al., [12] study that was conducted on 108 
patients with acute myocardial infarction supported by 
VA ECMO, where 35.5% of patients demonstrated 
successful weaning.  
 Echocardiography plays an important role in 
the management of VA ECMO patients. It is useful in-
patient assessment, cannulation, and detecting 
complications during ECMO run as well as the 
possibility of weaning from ECMO support [5]. 
In our study, a trial of ECMO removal was 
done on four patients based on the improvement of 
MAP, oxygenation, laboratory findings, EF, and aortic 
VTI. This is in agreement with the study done by 
Aissaoui, N et al., [10] which concluded that whenever 
the patient is under minimal ECMO support, LVEF of 
≥ 20–25%, and aortic VTI of ≥ 12 cm, ECMO removal 
should be considered. 
In our study, 4 patients were weaned from 
ECMO support after decreasing serum lactate; this is 
in agreement with Li et al., [13] who demonstrated that 
the initial lactate level and early lactate clearance in 
the 12 h following ECMO initiation were independent 
predictors of successful ECMO weaning. 
 
In our study, we gave levosimendan to 
1patient to facilitate weaning. After levosimendan 
treatment, the patient showed improvement in EF 
(20% before levosimendan treatment vs 30% 24 
hours after levosimendan treatment). This agrees with 
a study conducted on 6 patients by Affronti et al., who 
suggested that the treatment with levosimendan 
reduced the need for high-dose inotropes and 
facilitated weaning [14]. 
In femoral (VA -ECMO), vascular injuries and 
limb ischemia, unfortunately, occur as a result of the 
decrease of blood supply. In patients with a history of 
peripheral vascular disease, femoral cannulation 
should be avoided. 
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The present study demonstrated 1 patient 
who suffered from lower limb ischemia; however, 
reperfusion cannula was not inserted in this patient. 
It was noted that vascular complications were 
associated with unsuccessful weaning from ECMO 
and that leg ischemia is an independent risk factor for 
in-hospital death [15]. To minimise such 
complications, a distal perfusion cannula is placed in 
the superficial femoral artery [16]. 
Some studies have shown that neurologic 
complications are rather common among patients 
receiving ECMO. These complications are generally 
related to thrombosis with infarction or cerebral 
haemorrhage [17]. In our study, 2 patients suffered 
from intracerebral haemorrhage without surgical 
intervention. 
In a series of 87 adult patients, Matteen et al. 
found that 50% of the patients in their series suffered 
neurologic complications defined as stroke, 
intracerebral haemorrhage, seizure, encephalopathy, 
brain death, or coma. Moreover, they found that the 
increasing age was associated with higher rates of 
death and neurologic morbidity [17]. 
Lan et al., [18]
 
found that stroke affected 7% 
of the patients and was associated with significantly 
higher odds of death. In a meta-analysis of 1,866 
adult patients with cardiogenic shock, Cheng et al., 
[19]
 
found that stroke occurred in approximately 6% of 
the patients. 
In our study, 4 patients were successfully 
removed from ECMO support, but 3 patients were 
complicated by a secondary bacterial infection, and 
septic shock then died.  
A study conducted by Aubron et al., [20] on 
138 patients who received ECMO support showed 
that 36 patients had a total of 46 infections. These 
patients included 24 cases of bloodstream infection 
(BSI), 6 of these cases were secondary to ventilator-
associated pneumonia (VAP), 23 cases of VAP, and 5 
cases of catheter-associated urinary tract infection 
(CAUTI). The most frequent pathogens were 
Enterobacteriaceae (found in 16 of 46 cases), and 
Candida was the most common cause of BSI (in 9 of 
24 cases). The SOFA score before ECMO initiation 
and the number of days of support were 
independently associated with a risk of BSI.  
The lower incidence of weaning from VA 
ECMO and high mortality rate in our study could be 
attributed to severe comorbidities of the patients in our 
study where 3 patients had ARDS, 2 patients had 
post-CPR, and 1patient had a multivessel disease 
where CABG was done. 
 Limitations: This study represents the first 
Egyptian VA ECMO experience that had an impact on 
a small sample of patients. The financial constraints 
had an impact on the number of patients included in 
the study because of the high cost of VA ECMO run. 
Accordingly, the study was a single-centre study. 
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